Show
Sort by
-
- Journal Article
- A1
- open access
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD : a multicentre study
-
- Journal Article
- A2
- open access
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants : real-world evidence from MSBase
-
- Journal Article
- A1
- open access
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries : a propensity-score-matched cohort study
-
- Journal Article
- A1
- open access
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
-
- Journal Article
- A1
- open access
Disease activity in pregnant and postpartum women with multiple sclerosis receiving ocrelizumab or other disease-modifying therapies
-
- Journal Article
- A1
- open access
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic
-
- Journal Article
- A1
- open access
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis : recruitment challenges, potential bias, and statistical strategies
-
- Journal Article
- A1
- open access
Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis : a longitudinal analysis of global and national registries
-
- Journal Article
- A2
- open access
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis : results from the MSBase registry
-
- Journal Article
- A1
- open access
Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation